GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Current Ratio

RayzeBio (RayzeBio) Current Ratio : 31.85 (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. RayzeBio's current ratio for the quarter that ended in Sep. 2023 was 31.85.

RayzeBio has a current ratio of 31.85. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for RayzeBio's Current Ratio or its related term are showing as below:

RYZB' s Current Ratio Range Over the Past 10 Years
Min: 17.78   Med: 31.85   Max: 97.86
Current: 31.85

During the past 3 years, RayzeBio's highest Current Ratio was 97.86. The lowest was 17.78. And the median was 31.85.

RYZB's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.775 vs RYZB: 31.85

RayzeBio Current Ratio Historical Data

The historical data trend for RayzeBio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Current Ratio Chart

RayzeBio Annual Data
Trend Dec20 Dec21 Dec22
Current Ratio
97.86 33.00 28.69

RayzeBio Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial - - 28.69 17.78 31.85

Competitive Comparison of RayzeBio's Current Ratio

For the Biotechnology subindustry, RayzeBio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RayzeBio's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Current Ratio distribution charts can be found below:

* The bar in red indicates where RayzeBio's Current Ratio falls into.



RayzeBio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

RayzeBio's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=300.037/10.458
=28.69

RayzeBio's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=544.986/17.113
=31.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RayzeBio  (NAS:RYZB) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


RayzeBio Current Ratio Related Terms

Thank you for viewing the detailed overview of RayzeBio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RayzeBio (RayzeBio) Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.
Executives
Hauwermeiren Timothy Van director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi director SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. 10 percent owner 280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song director, officer: President and Chief Executive C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran officer: Chief Medical Officer 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p. 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129